Structure/histotoxicity relationship of parenteral iron preparations.
about
Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.The pharmacokinetics and pharmacodynamics of iron preparations.Benefits and risks of iron supplementation in anemic neonatal pigs.Iron supplementation in suckling piglets: how to correct iron deficiency anemia without affecting plasma hepcidin levels.A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.Do two intravenous iron sucrose preparations have the same efficacy?Iron, anaemia, and inflammatory bowel diseases.Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice.Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations.Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat modelDiluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability.The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?Stimulating erythropoiesis in inflammatory bowel disease associated anemia.Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.The Use of Magnetic Resonance Imaging for Non-Invasive Assessment of Venofer® Biodistribution in Rats.
P2860
Q28088503-2EEA4CB3-665F-435A-8458-0678232CB62DQ34000965-73DCEE2D-2866-4CB6-A2EA-49F1CE9A5399Q34039226-AFD30953-EA70-4DC9-9A49-C49F6939FA3BQ34086911-22B78745-2C77-49FF-87EB-70BB772C6AA0Q34758558-EFE63290-074E-48BB-A9EA-711C1F9735E0Q34764865-E752ABE3-BB1A-4E61-A534-DE8CF7F074EEQ35078212-00BB2C06-3E3A-4BCE-926E-3FBEFFF5CABCQ35344826-98DDD1E5-9B4F-45DC-BEB0-B324112C9A6FQ35596692-51A95AEC-4B4C-47EE-872B-23FD28247E0CQ35660777-8BE8EE85-9862-42AB-B814-8DE042C43219Q35898038-538AA5BB-ED5E-4D73-8364-A2AC792FCB8BQ35931905-A326953C-4A3D-4D90-8561-CC9E9614C974Q36475511-35381EF8-0AED-4179-AE38-141F2520E6A6Q36476581-9B7C66C0-4ACB-4ED1-80A1-205C4D3A6C46Q42276525-0DE981F1-8172-41F1-820B-3CF4BF2DF134Q42593974-C700DE31-653A-41FA-A2D4-1EC6AE959F64Q49300014-EB34D979-C727-449C-9090-0EE12D696E68Q55400937-E78FAC32-0B21-4F0E-B186-C29F5F00E50E
P2860
Structure/histotoxicity relationship of parenteral iron preparations.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Structure/histotoxicity relationship of parenteral iron preparations.
@en
Structure/histotoxicity relationship of parenteral iron preparations.
@nl
type
label
Structure/histotoxicity relationship of parenteral iron preparations.
@en
Structure/histotoxicity relationship of parenteral iron preparations.
@nl
prefLabel
Structure/histotoxicity relationship of parenteral iron preparations.
@en
Structure/histotoxicity relationship of parenteral iron preparations.
@nl
P2093
P1433
P1476
Structure/histotoxicity relationship of parenteral iron preparations.
@en
P2093
P304
P577
1992-12-01T00:00:00Z